Low expression of p63 and p73 in osteosarcoma

Tumori

Volumn 90, Issue 2, 2004, Pages 239-243

  Park, Hye Rim ^a   Kim, Youn Wha ^b   Park, Jae Hoon ^b   Maeng, Young Hee ^c   Nojima, Takayuki ^d   Hashimoto, Hiroshi ^e   Park, Yong Koo ^b,f  

^a Hallym University   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

^c Seoguipo Medical Center   (South Korea)

^d KANAZAWA MEDICAL UNIVERSITY   (Japan)

^e UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^f Kyung Hee University College of Medicine   (South Korea)

Author keywords

Osteosarcoma; P63; P73; Tumorigenesis

Indexed keywords

PROTEIN P53; PROTEIN P63; PROTEIN P73;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DNA BINDING; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOMA; OSTEOSARCOMA; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RNA SPLICING; SQUAMOUS CELL CARCINOMA; THYMOMA; TRANSACTIVATION; TRANSITIONAL CELL CARCINOMA;

EID: 2942564177     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160409000214     Document Type: Article

References (42)

1. Yokoyama R, Schneider-Stock R, Radig K, Wex T, Roessner A: Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosaromas: MDM2 amplification and p53 mutations found in progressive tumors. Pathol Res Pract, 194: 615-621, 1998.
2. Kawaguchi KI, Oda Y, Sakamoto A, Saito T, Tamiya S, Iwamoto Y, Tsuneyoshi M: Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years. Mod Pathol, 15: 878-888, 2002.
3. Lonardo F, Ueda T, Huvos AG, Healey J, Ladanyi M: p53 and MDM2 alterations in osteosarcomas. Correlation with clinicopathologic features and proliferative rate. Cancer, 79: 1541-1547, 1997.
4. Choi HR, Batsakis JG, Zhan F, Sturgis E, Luna MA, El-Naggar AK: Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Hum Pathol, 33: 158-164, 2002.
5. Yang A, McKeon F: p63 and p73: p53 mimics, menaces, and more. Nat Rev Mol Cell Biol, 1: 199-207, 2000.
6. Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Teruya-Feldstein J, Pohar K, Hoos A, Cordon-Cardo C: p63 expression profiles in human normal and tumor tissues. Clin Cancer Res, 8: 494-501, 2002.
7. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A: p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature, 398: 708-713, 1999.
8. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, McKeon F: p63 is essential for regenerative proliferation in limb, craniofacial, and epithelial development. Nature, 298: 714-718, 1999.
9. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D, McKeon F: p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell, 2: 305-316, 1998.
10. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C: A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol, 21: 1874-1887, 2001.
11. Hall PA, Campbell SJ, O'Neill M, Royston DJ, Nylander K, Carey FA, Kernohan NM: Expression of the p53 homologue p63α and dNp63α in normal and neoplastic cells. Carcinogenesis, 21: 153-160, 2000.
12. Chen X: The p53 family: same response, different signals? Mol Med Today, 5: 387-392, 1999.
13. Weith A, Martinsson T, Cziepluch C, Bruderlein S, Amler LC, Berthold F, Schwab M: Neuroblastoma consensus deletion maps to 1036.1-2. Genes Chromosomes Cancer, 1: 159-166, 1989.
14. Nomoto S, Haruki N, Kondo M, Konishi H, Takahashi T: Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res, 58: 1380-1383, 1998.
15. Takahashi H, Ichimiya S, Nimura Y, Watanabe M, Furusato M, Wakui S, Yatani R, Aizawa S, Nakagawara A: Mutation, allelotyping and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res, 58: 2076-2077, 1998.
16. Corn PG, Kuerbitz SJ, van Noesel MM, Esteller M, Compitello N, Baylin SB, Herman JG: Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation. Cancer Res, 59: 3352-3356, 1999.
17. Mai M, Qian C, Yokomizo A, Tindall DJ, Bostwick D, Polychronakos C, Smith DL, Liu W: Loss of imprinting and allele switching of p73 in renal cell carcinoma. Oncogene, 17: 1739-1741, 1998.
18. Chi SG, deVere White RW, Meyers FJ, Siders D, Lee F, Gumerlock PH: p53 in prostate: frequent expressed transition mutations. J Natl Cacer Inst, 86: 926-933, 1994.
19. Stiewe T, Putzer BM: Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Diff, 9: 237-245, 2002.
20. Bodey B, Groger AM, Bodey B Jr, Siegel S, Kaiser HE: Immunohistochemical detection of p53 protein overexpression in primary human osteosarcomas. Anticancer Res, 17: 493-498, 1997.
21. Radig K, Schneider-Stock R, Haeckel C, Neumann W, Roessner A: p53 gene mutation in osteosarcomas of low-grade malignancy. Hum Pathol, 29: 1310-1316, 1998.
22. Park HR, Park YK: Expression of p53 protein, PCNA, and Ki-67 in osteosarcomas of bone. J Kor Med Sci, 10: 360-367, 1995.
23. Sheikh MS, Fornace AJ Jr: Role of p53 family members in apoptosis. J Cell Physiol, 182: 171-181, 2000.
24. Park BJ, Lee SJ, Kim JI, Lee SU, Lee CH, Chang SG, Park JH, Chi SG: Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res, 60: 3370-3374, 2000.
25. Quade BJ, Yang A, Wang Y, Sun D, Park JJ, Sheets EE, Cviko A, Federschneider JM, Peters R, McKeon FD, Crum CP: Expression of the p53 homologue p63 in early cervical neoplasia. Gynecol Oncol, 80: 24-29, 2001.
26. Hagiwara K, McMenamin MG, Miura K, Harris CC: Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. Cancer Res, 59: 4165-4169, 1999.
27. Sunahara M, Shishikura T, Takahashi M, Todo S, Yamamoto N, Kimura H, Kato S, Ishioka C, Ikawa Y, Nakagawara A: Mutational analysis of p51A/TAp63γ, a p53 homolog, in non-small cell lung cancer and breast cancer. Oncogene, 18: 3761-3765, 1999.
28. Bjorkqvist AM, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Tammilehto L, Mattson K, Vainio H, Knuutila S: DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes Chromosomes Cancer, 22: 79-82, 1998.
29. Bockmuhl U, Schwendel A, Dietel M, Petersen I: Distinct patterns of chromosomal alterations in high- and low-grade head and neck squamous cell carcinomas. Cancer Res, 56: 5325-5329, 1996.
30. Parsa R, Yang A, McKeon F, Green H: Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J Investig Dermatol, 113: 1099-1105, 1999.
31. Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE, Ratovitski EA, Jen J, Sidransky D: AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA, 97: 5462-5467, 2000.
32. Wang TY, Chen BF, Yang YC, Chen H, Wang Y, Cviko A, Quade BJ, Sun D, Yang A, McKeon FD, Crum CP: Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. Hum Pathol, 32: 479-496, 2001.
33. Glickman JN, Yang A, Shahsafaei A, McKeon F, Odze RD: Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum Pathol, 32: 1157-1165, 2001.
34. Kaufmann O, Fietze E, Mengs J, Dietel M: Value of p63 and cytokeratin 5/ 6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol, 116: 823-830, 2001.
35. Barbareschi M, Pecciarini L, Cangi MG, Macri E, Rizzo A, Viale G, Doglioni C: p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol, 25: 1054-1060, 2001.
36. Parsons JK, Gage WR, Nelson WG, De Marzo AM: p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology, 58: 619-624, 2001.
37. Tannapfel A, Schmelzer S, Benicke M, Klimpfinger M, Kohlhaw K, Mossner J, Engeland K, Wittekind C: Expression of the p53 homologues p63 and p73 in multiple simultaneous gastric cancer. J Pathol, 195: 163-170, 2001.
38. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D: Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell, 90: 809-819, 1997.
39. Martinez-Delgado B, Melendez B, Cuadros M, Garcia MJ, Nomdedeu J, Rivas C, Fernandez-Piqueras J, Benitez J: Frequent inactivation of the p73 gene by abnormal methylation or LOH in non-Hodgkin's lymphomas. Int J Cancer, 102: 15-19, 2002.
40. Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I, Ikawa Y, Nimura Y, Nakagawara A, Obinata M, Ikawa S: Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med, 4: 839-843, 1998.
41. Ikawa S, Nakagawara A, Ikawa Y: p53 family genes: structural comparison, expression, and mutation. Cell Death Differ, 6: 1154-1161, 1999.
42. Roth J, Dobbelstein M: Failure of viral oncoproteins to target the p53-homologue p51A. J Gen Virol, 80: 3251-3255, 1999.